CFDB - Cystic Fibrosis DataBase

Cochrane Database of Systematic Reviews - Cochrane Review

Medical interventions for chronic rhinosinusitis in cystic fibrosis

Study design (if review, criteria of inclusion for studies)

Randomized and quasi‐randomized trials of different medical interventions compared to each other or to no intervention or to placebo.


Patiens with CF and rhinosinusitis


medical interventions (e. g. different concentrations of nasal saline irrigations, topical or oral corticosteroids, antibiotics ‐ including nebulized antibiotics, dornase alfa and modulators of the cystic fibrosis transmembrane conductance regulator (CFTR) such as lumacaftor, ivacaftor or tezacaftor) compared to each other or to no intervention or to placebo

Outcome measures

improvement of rhinosinusitis, preventing pulmonary exacerbations, improving quality of life

Main results

We identified no trials that met the pre‐defined inclusion criteria. The most recent searches identified 44 new references, none of which were eligible for inclusion in the current version of this review; 12 studies are listed as excluded and one as ongoing.

Authors' conclusions

We identified no eligible trials assessing the medical interventions in people with cystic fibrosis and chronic rhinosinusitis. High‐quality trials are needed which should assess the efficacy of different treatment options detailed above for managing chronic rhinosinusitis, preventing pulmonary exacerbations and improving quality of life in people with cystic fibrosis.

Keywords: Adolescent; Adult; Bacterial Infections; Child; Deoxyribonuclease; Infection; Inhalation OR nebulised; nebuliser; non pharmacological intervention - devices OR physiotherapy; pharmacological_intervention; Recombinant Proteins; Respiratory Tract Infections; Sinusitis; Airway clearance drugs -expectorants- mucolytic- mucociliary-; Respiratory System Agents; Respiratory Tract Diseases; Dornase alpha; Pulmozyme; Hypertonic Solutions; isotonic Solutions;